Ekso Bionics Holdings, Inc. (EKSO) 10-Year Financial Performance & Capital Metrics

EKSO • • Industrial / General

HealthcareMedical InstrumentsWound Care & Therapeutic DevicesSpecialized Therapeutic Devices

AboutEkso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. The company operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. It also provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; and EksoUE is a wearable upper extremity assistive device that helps to reduce the effect of gravity on the wearer's shoulders and arms. Ekso Bionics Holdings, Inc. has a license agreement with Lockheed Martin Corporation. The company was incorporated in 2005 and is headquartered in Richmond, California.Show more

Revenue $18M -1.9%
EBITDA -$9M +34.0%
Net Income -$11M +25.5%
EPS (Diluted) -0.56 +49.1%
Gross Margin 53.06% +6.8%
EBITDA Margin -49.38% +32.7%
Operating Margin -58.35% +29.4%
Net Margin -63.21% +24.0%
ROE -89.52% -12.1%
ROIC -67.24% +30.1%
Debt/Equity 0.47 -17.2%
Interest Coverage -38.88 +22.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 94 (top 6%)

✗Weaknesses

✗Negative free cash flow
✗Shares diluted 45.4% in last year
✗Trading more than 30% below 52-week high
✗Expensive at 13.6x book value

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y12.9%

5Y5.19%

3Y16.81%

TTM-16.59%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM6.26%

EPS CAGR

10Y-

5Y-

3Y-

TTM-212.31%

ROCE

10Y Avg-94.16%

5Y Avg-57.26%

3Y Avg-50.67%

Latest-52.41%

Peer Comparison

Specialized Therapeutic Devices

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
RMDResMed Inc.	38.05B	260.70	27.41	9.84%	27.35%	23.49%	4.37%	0.14
ZJYLJin Medical International Ltd.	22.54M	0.14	6.13	18.57%	10.94%	16.93%		0.41
FEMYFemasys Inc.	38.2M	0.64	-0.76	51.97%	-9.61%	-434.6%		3.23
NYXHNyxoah S.A.	221.59M	5.15	-2.85	3.98%	-14.85%	-164.31%		0.20
MLSSMilestone Scientific Inc.	22.8M	0.29	-4.91	-12.19%	-76.78%	-208.8%		0.06
NVCRNovoCure Limited	1.55B	13.80	-8.85	18.82%	-27.66%	-52.05%		1.90
EKSOEkso Bionics Holdings, Inc.	22.43M	8.55	-15.27	-1.94%	-70.74%	-107.8%		0.47
PLSEPulse Biosciences, Inc.	955.52M	14.10	-15.33		-868.99%	-80.62%		0.08

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	8.66M	14.22M	7.35M	11.33M	13.92M	8.88M	11.25M	12.91M	18.28M	17.93M
Revenue Growth %	0.63%	0.64%	-0.48%	0.54%	0.23%	-0.36%	0.27%	0.15%	0.42%	-0.02%
Cost of Goods Sold+	7.48M	11.27M	5.28M	7.02M	7.15M	3.81M	4.5M	6.7M	9.2M	8.41M
COGS % of Revenue	0.86%	0.79%	0.72%	0.62%	0.51%	0.43%	0.4%	0.52%	0.5%	0.47%
Gross Profit+	1.18M	2.95M	2.07M	4.31M	6.76M	5.07M	6.75M	6.21M	9.08M	9.51M
Gross Margin %	0.14%	0.21%	0.28%	0.38%	0.49%	0.57%	0.6%	0.48%	0.5%	0.53%
Gross Profit Growth %	-0.24%	1.5%	-0.3%	1.08%	0.57%	-0.25%	0.33%	-0.08%	0.46%	0.05%
Operating Expenses+	22.74M	30.73M	33.35M	31.37M	23.4M	17.93M	20.58M	21.77M	24.19M	19.97M
OpEx % of Revenue	2.63%	2.16%	4.54%	2.77%	1.68%	2.02%	1.83%	1.69%	1.32%	1.11%
Selling, General & Admin	16.26M	21.85M	23.87M	25.53M	18.81M	15.45M	17.83M	18.14M	19.17M	16.1M
SG&A % of Revenue	1.88%	1.54%	3.25%	2.25%	1.35%	1.74%	1.59%	1.41%	1.05%	0.9%
Research & Development	6.48M	8.88M	9.48M	5.85M	4.6M	2.47M	2.75M	3.63M	5.03M	3.87M
R&D % of Revenue	0.75%	0.62%	1.29%	0.52%	0.33%	0.28%	0.24%	0.28%	0.27%	0.22%
Other Operating Expenses	-45K	-166K	296K	0	0	0	0	0	0	0
Operating Income+	-21.56M	-27.59M	-31.61M	-27.03M	-16.64M	-12.86M	-13.83M	-15.56M	-15.11M	-10.46M
Operating Margin %	-2.49%	-1.94%	-4.3%	-2.39%	-1.2%	-1.45%	-1.23%	-1.2%	-0.83%	-0.58%
Operating Income Growth %	-0.28%	-0.28%	-0.15%	0.14%	0.38%	0.23%	-0.08%	-0.12%	0.03%	0.31%
EBITDA+	-20.63M	-25.73M	-29.88M	-25.53M	-15.95M	-12.24M	-13.27M	-14.67M	-13.41M	-8.85M
EBITDA Margin %	-2.38%	-1.81%	-4.06%	-2.25%	-1.15%	-1.38%	-1.18%	-1.14%	-0.73%	-0.49%
EBITDA Growth %	-0.29%	-0.25%	-0.16%	0.15%	0.38%	0.23%	-0.08%	-0.11%	0.09%	0.34%
D&A (Non-Cash Add-back)	933K	1.85M	1.73M	1.5M	690K	620K	561K	887K	1.7M	1.61M
EBIT	-19.58M	-23.45M	-28.47M	-26.39M	-11.75M	-15.69M	-9.65M	-14.92M	-14.9M	-11.06M
Net Interest Income+	-2K	-4K	-648K	-600K	-1.48M	-139K	-113K	-156K	-302K	-269K
Interest Income	11K	12K	0	0	384K	0	0	0	0	0
Interest Expense	13K	16K	648K	600K	384K	139K	113K	156K	302K	269K
Other Income/Expense	1.97M	4.12M	2.49M	38K	4.51M	-2.97M	4.06M	476K	-86K	-870K
Pretax Income+	-19.59M	-23.47M	-29.12M	-26.99M	-12.13M	-15.82M	-9.76M	-15.08M	-15.2M	-11.33M
Pretax Margin %	-2.26%	-1.65%	-3.96%	-2.38%	-0.87%	-1.78%	-0.87%	-1.17%	-0.83%	-0.63%
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-19.59M	-23.47M	-29.12M	-26.99M	-12.13M	-15.82M	-9.76M	-15.08M	-15.2M	-11.33M
Net Margin %	-2.26%	-1.65%	-3.96%	-2.38%	-0.87%	-1.78%	-0.87%	-1.17%	-0.83%	-0.63%
Net Income Growth %	0.42%	-0.2%	-0.24%	0.07%	0.55%	-0.3%	0.38%	-0.54%	-0.01%	0.25%
Net Income (Continuing)	-19.59M	-23.47M	-29.12M	-26.99M	-12.13M	-15.82M	-9.76M	-15.08M	-15.2M	-11.33M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-15.52	-18.90	-12.27	-6.61	-2.44	-2.21	-0.88	-1.16	-1.10	-0.56
EPS Growth %	0.56%	-0.22%	0.35%	0.46%	0.63%	0.09%	0.6%	-0.32%	0.05%	0.49%
EPS (Basic)	-15.53	-19.42	-12.27	-6.61	-2.44	-2.21	-0.80	-1.16	-1.10	-0.56
Diluted Shares Outstanding	1.26M	1.24M	2.37M	4.08M	4.79M	7.16M	12.27M	12.96M	13.87M	20.16M
Basic Shares Outstanding	1.26M	1.21M	2.37M	4.08M	4.79M	7.16M	12.19M	12.96M	13.87M	20.16M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	25.2M	20.68M	34.94M	14.97M	18.81M	18.42M	47.8M	31.04M	20.21M	18.84M
Cash & Short-Term Investments	19.55M	16.85M	27.81M	7.66M	10.87M	12.86M	40.41M	20.52M	8.64M	6.49M
Cash Only	19.55M	16.85M	27.81M	7.66M	10.87M	12.86M	40.41M	20.52M	8.64M	6.49M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	2.07M	1.78M	2.76M	3.66M	5.21M	3.39M	4.66M	4.63M	5.64M	7.24M
Days Sales Outstanding	87.19	45.69	137.01	117.89	136.59	139.27	151.31	130.74	112.72	147.38
Inventory	1.06M	1.56M	3.02M	3.37M	2.49M	1.98M	2.24M	5.19M	5.05M	4.57M
Days Inventory Outstanding	51.52	50.38	208.96	175.2	127.01	189.39	181.97	282.66	200.35	198.29
Other Current Assets	2.09M	502K	1.34M	281K	238K	191K	0	700K	875K	541K
Total Non-Current Assets+	7M	3.74M	3.05M	2.69M	3.11M	2.18M	1.37M	9.87M	8.71M	7.81M
Property, Plant & Equipment	2.63M	2.44M	2.25M	2.37M	2.74M	1.86M	1.21M	3.99M	3M	2.37M
Fixed Asset Turnover	3.30x	5.84x	3.27x	4.79x	5.08x	4.78x	9.32x	3.24x	6.10x	7.58x
Goodwill	189K	189K	189K	189K	189K	0	0	431K	431K	431K
Intangible Assets	1.58M	1.03M	491K	0	0	0	0	5.22M	4.89M	4.58M
Long-Term Investments	0	0	0	0	36K	0	0	0	0	0
Other Non-Current Assets	2.6M	91K	122K	134K	142K	320K	164K	231K	392K	433K
Total Assets+	32.2M	24.43M	37.99M	17.66M	21.91M	20.6M	49.17M	40.9M	28.92M	26.65M
Asset Turnover	0.27x	0.58x	0.19x	0.64x	0.64x	0.43x	0.23x	0.32x	0.63x	0.67x
Asset Growth %	-0.04%	-0.24%	0.56%	-0.54%	0.24%	-0.06%	1.39%	-0.17%	-0.29%	-0.08%
Total Current Liabilities+	8.62M	6.31M	9.16M	10.13M	7.83M	4.97M	6.86M	9.2M	8.12M	7.54M
Accounts Payable	2.69M	1.88M	2.42M	3.16M	1.9M	1.5M	3.11M	3.15M	1.85M	1.55M
Days Payables Outstanding	131.42	60.83	167.16	164.02	97.11	143.72	252.18	171.71	73.28	67.33
Short-Term Debt	80K	54K	2.14M	2.33M	2.77M	548K	0	2.31M	1.25M	1.25M
Deferred Revenue (Current)	1000K	825K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	682K	2.31M	1.24M	1.06M	567K	235K	0	0	606K	0
Current Ratio	2.92x	3.28x	3.81x	1.48x	2.40x	3.70x	6.97x	3.37x	2.49x	2.50x
Quick Ratio	2.80x	3.03x	3.48x	1.14x	2.08x	3.31x	6.65x	2.81x	1.87x	1.89x
Cash Conversion Cycle	7.29	35.23	178.8	129.06	166.49	184.94	81.1	241.69	239.8	278.35
Total Non-Current Liabilities+	14.77M	11.58M	7.43M	4.79M	7.29M	11.19M	5.09M	6.26M	8.2M	6.41M
Long-Term Debt	0	6.79M	4.83M	2.65M	407K	3.08M	1.99M	3.77M	4.83M	3.85M
Capital Lease Obligations	0	0	0	0	711K	233K	0	1.09M	723K	452K
Deferred Tax Liabilities	-21K	3.55M	1.65M	585K	0	0	0	0	0	0
Other Non-Current Liabilities	10.16M	3.99M	1.79M	652K	4.38M	6.08M	1.62M	374K	471K	182K
Total Liabilities	23.39M	17.89M	16.6M	14.93M	15.12M	16.16M	11.95M	15.46M	16.31M	13.95M
Total Debt+	80K	6.84M	7M	4.98M	3.89M	3.86M	2.22M	7.5M	7.17M	5.98M
Net Debt	-19.47M	-10M	-20.81M	-2.67M	-6.98M	-9.01M	-38.18M	-13.02M	-1.47M	-510K
Debt / Equity	0.01x	1.05x	0.33x	1.83x	0.57x	0.87x	0.06x	0.29x	0.57x	0.47x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-1658.54x	-1724.13x	-48.78x	-45.05x	-43.33x	-92.50x	-122.37x	-99.72x	-50.04x	-38.88x
Total Equity+	8.81M	6.53M	21.39M	2.73M	6.8M	4.43M	37.22M	25.44M	12.61M	12.71M
Equity Growth %	-0.61%	-0.26%	2.28%	-0.87%	1.49%	-0.35%	7.39%	-0.32%	-0.5%	0.01%
Book Value per Share	6.98	5.26	9.01	0.67	1.42	0.62	3.03	1.96	0.91	0.63
Total Shareholders' Equity	8.81M	6.53M	21.39M	2.73M	6.8M	4.43M	37.22M	25.44M	12.61M	12.71M
Common Stock	105K	22K	60K	63K	87K	8K	13K	13K	15K	22K
Retained Earnings	-91.39M	-114.86M	-144.15M	-171.15M	-183.28M	-199.1M	-208.87M	-223.95M	-239.15M	-250.47M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-1K	79K	-340K	-92K	50K	-847K	-17K	563K	156K	957K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-18.27M	-25M	-31.23M	-22.16M	-15.77M	-8.76M	-11.16M	-14.69M	-12.05M	-9.85M
Operating CF Margin %	-2.11%	-1.76%	-4.25%	-1.96%	-1.13%	-0.99%	-0.99%	-1.14%	-0.66%	-0.55%
Operating CF Growth %	-0.22%	-0.37%	-0.25%	0.29%	0.29%	0.44%	-0.27%	-0.32%	0.18%	0.18%
Net Income	-19.59M	-23.47M	-29.12M	-26.99M	-12.13M	-15.82M	-9.76M	-15.08M	-15.2M	-11.33M
Depreciation & Amortization	933K	1.85M	1.73M	1.51M	690K	620K	561K	887K	1.7M	1.61M
Stock-Based Compensation	1.73M	3.12M	2.92M	3.08M	2.4M	2.58M	2.5M	2.73M	2.24M	1.63M
Deferred Taxes	-2.5M	-4.15M	-3.24M	-606K	-5.87M	2.43M	-4.12M	0	0	0
Other Non-Cash Items	484K	-202K	55K	308K	1.16M	319K	134K	-647K	-207K	771K
Working Capital Changes	678K	-2.15M	-3.58M	530K	-2.02M	1.12M	-468K	-2.58M	-583K	-2.52M
Change in Receivables	-520K	154K	-1.08M	-850K	-1.6M	1.75M	-1.62M	-67K	-1.21M	-1.97M
Change in Inventory	-200K	-541K	-2.1M	-1.66M	893K	379K	-752K	-1.4M	232K	257K
Change in Payables	1.74M	-818K	77K	752K	-1.23M	-402K	1.61M	-102K	-1.31M	-288K
Cash from Investing+	-1.49M	-1.1M	-456K	-131K	-60K	0	-59K	-5.17M	-157K	-37K
Capital Expenditures	-1.49M	-1.1M	-456K	-131K	-60K	0	-59K	-194K	-157K	-37K
CapEx % of Revenue	0.17%	0.08%	0.06%	0.01%	0%	-	0.01%	0.02%	0.01%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	19K	0	0
Cash from Financing+	14.12M	23.31M	42.57M	2.27M	19.04M	10.7M	38.71M	0	348K	7.77M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	-10.35M	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	12.28M	159K	1K	228K	3.33M	1.42M	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-19.76M	-26.09M	-31.68M	-22.3M	-15.83M	-8.76M	-11.21M	-14.88M	-12.21M	-9.88M
FCF Margin %	-2.28%	-1.83%	-4.31%	-1.97%	-1.14%	-0.99%	-1%	-1.15%	-0.67%	-0.55%
FCF Growth %	-0.2%	-0.32%	-0.21%	0.3%	0.29%	0.45%	-0.28%	-0.33%	0.18%	0.19%
FCF per Share	-15.66	-21.02	-13.35	-5.46	-3.30	-1.22	-0.91	-1.15	-0.88	-0.49
FCF Conversion (FCF/Net Income)	0.93x	1.07x	1.07x	0.82x	1.30x	0.55x	1.14x	0.97x	0.79x	0.87x
Interest Paid	12K	16K	429K	457K	309K	109K	104K	126K	191K	182K
Taxes Paid	5K	33K	20K	18K	23K	6K	1K	13K	45K	8K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-123.96%	-306.02%	-208.6%	-223.82%	-254.74%	-281.81%	-46.88%	-48.13%	-79.89%	-89.52%
Return on Invested Capital (ROIC)	-	-	-	-6385.04%	-	-	-	-203.67%	-96.22%	-67.24%
Gross Margin	13.61%	20.72%	28.14%	38.03%	48.6%	57.08%	60.01%	48.13%	49.67%	53.06%
Net Margin	-226.19%	-165.04%	-396.06%	-238.19%	-87.17%	-178.17%	-86.82%	-116.79%	-83.14%	-63.21%
Debt / Equity	0.01x	1.05x	0.33x	1.83x	0.57x	0.87x	0.06x	0.29x	0.57x	0.47x
Interest Coverage	-1658.54x	-1724.13x	-48.78x	-45.05x	-43.33x	-92.50x	-122.37x	-99.72x	-50.04x	-38.88x
FCF Conversion	0.93x	1.07x	1.07x	0.82x	1.30x	0.55x	1.14x	0.97x	0.79x	0.87x
Revenue Growth	62.59%	64.2%	-48.29%	54.11%	22.81%	-36.18%	26.62%	14.81%	41.57%	-1.94%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Product	-	-	-	8.76M	10.79M	-	-	-	14.13M	-
Product Growth	-	-	-	-	23.13%	-	-	-	-	-
Service	-	-	-	2.1M	2.56M	-	-	-	2.82M	-
Service Growth	-	-	-	-	21.90%	-	-	-	-	-
Subscription	-	-	-	-	-	-	-	-	967K	-
Subscription Growth	-	-	-	-	-	-	-	-	-	-
Product and Service, Other	-	-	-	441K	493K	-	-	-	359K	-
Product and Service, Other Growth	-	-	-	-	11.79%	-	-	-	-	-
EksoHealth	-	-	-	-	-	8.07M	9.75M	11.83M	-	-
EksoHealth Growth	-	-	-	-	-	-	20.88%	21.33%	-	-
EksoWorks	-	-	-	-	-	816K	1.5M	1.08M	-	-
EksoWorks Growth	-	-	-	-	-	-	83.33%	-27.67%	-	-
Collaborative Arrangements	-	-	-	28K	74K	-	-	-	-	-
Collaborative Arrangements Growth	-	-	-	-	164.29%	-	-	-	-	-
Medical	-	-	5.83M	-	-	-	-	-	-	-
Medical Growth	-	-	-	-	-	-	-	-	-	-
Industrial	-	-	1.48M	-	-	-	-	-	-	-
Industrial Growth	-	-	-	-	-	-	-	-	-	-
Engineering Services	4.41M	887K	38K	-	-	-	-	-	-	-
Engineering Services Growth	-	-79.88%	-95.72%	-	-	-	-	-	-	-
Medical Devices	4.25M	12.08M	-	-	-	-	-	-	-	-
Medical Devices Growth	-	184.13%	-	-	-	-	-	-	-	-
Industrial Sales	-	1.25M	-	-	-	-	-	-	-	-
Industrial Sales Growth	-	-	-	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Americas	-	-	-	-	-	-	-	6.81M	-	10.13M
Americas Growth	-	-	-	-	-	-	-	-	-	-
UNITED STATES	-	-	-	7.03M	9.07M	5.95M	-	6.56M	-	9.71M
UNITED STATES Growth	-	-	-	-	29.07%	-34.46%	-	-	-	-
EMEA	-	-	-	-	-	-	-	3.85M	-	5.94M
EMEA Growth	-	-	-	-	-	-	-	-	-	-
FRANCE	-	-	-	-	-	-	-	-	-	3.01M
FRANCE Growth	-	-	-	-	-	-	-	-	-	-
Other Country	-	-	-	-	-	-	-	-	-	2.94M
Other Country Growth	-	-	-	-	-	-	-	-	-	-
Asia Pacific	-	-	-	-	-	-	-	2.25M	-	1.85M
Asia Pacific Growth	-	-	-	-	-	-	-	-	-	-
Americas Other	-	-	-	-	-	-	-	-	-	421K
Americas Other Growth	-	-	-	-	-	-	-	-	-	-
INDONESIA	-	-	-	-	-	-	-	-	18.28M	-
INDONESIA Growth	-	-	-	-	-	-	-	-	-	-
POLAND	-	-	-	-	-	-	-	-	1.41M	-
POLAND Growth	-	-	-	-	-	-	-	-	-	-
EMEA, Other	-	-	-	-	-	-	-	2.85M	-	-
EMEA, Other Growth	-	-	-	-	-	-	-	-	-	-
GERMANY	-	-	-	-	-	-	-	1M	-	-
GERMANY Growth	-	-	-	-	-	-	-	-	-	-
Americas, Other	-	-	-	-	-	-	-	252K	-	-
Americas, Other Growth	-	-	-	-	-	-	-	-	-	-
Non-US	-	-	-	4.3M	4.85M	2.94M	-	-	-	-
Non-US Growth	-	-	-	-	12.59%	-39.39%	-	-	-	-
United States	-	9.04M	4.96M	-	-	-	-	-	-	-
United States Growth	-	-	-45.17%	-	-	-	-	-	-	-
All Other	-	5.18M	2.4M	-	-	-	-	-	-	-
All Other Growth	-	-	-53.76%	-	-	-	-	-	-	-
North America	6.69M	-	-	-	-	-	-	-	-	-
North America Growth	-	-	-	-	-	-	-	-	-	-
Other Geographical	1.97M	-	-	-	-	-	-	-	-	-
Other Geographical Growth	-	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Ekso Bionics Holdings, Inc. (EKSO) reported $14.7M in revenue for fiscal year 2024. This represents a 347% increase from $3.3M in 2013.

Ekso Bionics Holdings, Inc. (EKSO) saw revenue decline by 1.9% over the past year.

Ekso Bionics Holdings, Inc. (EKSO) reported a net loss of $10.4M for fiscal year 2024.

Dividend & Returns

Ekso Bionics Holdings, Inc. (EKSO) has a return on equity (ROE) of -89.5%. Negative ROE indicates the company is unprofitable.

Ekso Bionics Holdings, Inc. (EKSO) had negative free cash flow of $8.9M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Ekso Bionics Holdings, Inc. (EKSO) 10-Year Financial Performance & Capital Metrics

EKSO • • Industrial / General

HealthcareMedical InstrumentsWound Care & Therapeutic DevicesSpecialized Therapeutic Devices

Revenue $18M -1.9%
EBITDA -$9M +34.0%
Net Income -$11M +25.5%
EPS (Diluted) -0.56 +49.1%
Gross Margin 53.06% +6.8%
EBITDA Margin -49.38% +32.7%
Operating Margin -58.35% +29.4%
Net Margin -63.21% +24.0%
ROE -89.52% -12.1%
ROIC -67.24% +30.1%
Debt/Equity 0.47 -17.2%
Interest Coverage -38.88 +22.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 94 (top 6%)

✗Weaknesses

✗Negative free cash flow
✗Shares diluted 45.4% in last year
✗Trading more than 30% below 52-week high
✗Expensive at 13.6x book value

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y12.9%

5Y5.19%

3Y16.81%

TTM-16.59%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM6.26%

EPS CAGR

10Y-

5Y-

3Y-

TTM-212.31%

ROCE

10Y Avg-94.16%

5Y Avg-57.26%

3Y Avg-50.67%

Latest-52.41%

Peer Comparison

Specialized Therapeutic Devices

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
RMDResMed Inc.	38.05B	260.70	27.41	9.84%	27.35%	23.49%	4.37%	0.14
ZJYLJin Medical International Ltd.	22.54M	0.14	6.13	18.57%	10.94%	16.93%		0.41
FEMYFemasys Inc.	38.2M	0.64	-0.76	51.97%	-9.61%	-434.6%		3.23
NYXHNyxoah S.A.	221.59M	5.15	-2.85	3.98%	-14.85%	-164.31%		0.20
MLSSMilestone Scientific Inc.	22.8M	0.29	-4.91	-12.19%	-76.78%	-208.8%		0.06
NVCRNovoCure Limited	1.55B	13.80	-8.85	18.82%	-27.66%	-52.05%		1.90
EKSOEkso Bionics Holdings, Inc.	22.43M	8.55	-15.27	-1.94%	-70.74%	-107.8%		0.47
PLSEPulse Biosciences, Inc.	955.52M	14.10	-15.33		-868.99%	-80.62%		0.08

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	8.66M	14.22M	7.35M	11.33M	13.92M	8.88M	11.25M	12.91M	18.28M	17.93M
Revenue Growth %	0.63%	0.64%	-0.48%	0.54%	0.23%	-0.36%	0.27%	0.15%	0.42%	-0.02%
Cost of Goods Sold+	7.48M	11.27M	5.28M	7.02M	7.15M	3.81M	4.5M	6.7M	9.2M	8.41M
COGS % of Revenue	0.86%	0.79%	0.72%	0.62%	0.51%	0.43%	0.4%	0.52%	0.5%	0.47%
Gross Profit+	1.18M	2.95M	2.07M	4.31M	6.76M	5.07M	6.75M	6.21M	9.08M	9.51M
Gross Margin %	0.14%	0.21%	0.28%	0.38%	0.49%	0.57%	0.6%	0.48%	0.5%	0.53%
Gross Profit Growth %	-0.24%	1.5%	-0.3%	1.08%	0.57%	-0.25%	0.33%	-0.08%	0.46%	0.05%
Operating Expenses+	22.74M	30.73M	33.35M	31.37M	23.4M	17.93M	20.58M	21.77M	24.19M	19.97M
OpEx % of Revenue	2.63%	2.16%	4.54%	2.77%	1.68%	2.02%	1.83%	1.69%	1.32%	1.11%
Selling, General & Admin	16.26M	21.85M	23.87M	25.53M	18.81M	15.45M	17.83M	18.14M	19.17M	16.1M
SG&A % of Revenue	1.88%	1.54%	3.25%	2.25%	1.35%	1.74%	1.59%	1.41%	1.05%	0.9%
Research & Development	6.48M	8.88M	9.48M	5.85M	4.6M	2.47M	2.75M	3.63M	5.03M	3.87M
R&D % of Revenue	0.75%	0.62%	1.29%	0.52%	0.33%	0.28%	0.24%	0.28%	0.27%	0.22%
Other Operating Expenses	-45K	-166K	296K	0	0	0	0	0	0	0
Operating Income+	-21.56M	-27.59M	-31.61M	-27.03M	-16.64M	-12.86M	-13.83M	-15.56M	-15.11M	-10.46M
Operating Margin %	-2.49%	-1.94%	-4.3%	-2.39%	-1.2%	-1.45%	-1.23%	-1.2%	-0.83%	-0.58%
Operating Income Growth %	-0.28%	-0.28%	-0.15%	0.14%	0.38%	0.23%	-0.08%	-0.12%	0.03%	0.31%
EBITDA+	-20.63M	-25.73M	-29.88M	-25.53M	-15.95M	-12.24M	-13.27M	-14.67M	-13.41M	-8.85M
EBITDA Margin %	-2.38%	-1.81%	-4.06%	-2.25%	-1.15%	-1.38%	-1.18%	-1.14%	-0.73%	-0.49%
EBITDA Growth %	-0.29%	-0.25%	-0.16%	0.15%	0.38%	0.23%	-0.08%	-0.11%	0.09%	0.34%
D&A (Non-Cash Add-back)	933K	1.85M	1.73M	1.5M	690K	620K	561K	887K	1.7M	1.61M
EBIT	-19.58M	-23.45M	-28.47M	-26.39M	-11.75M	-15.69M	-9.65M	-14.92M	-14.9M	-11.06M
Net Interest Income+	-2K	-4K	-648K	-600K	-1.48M	-139K	-113K	-156K	-302K	-269K
Interest Income	11K	12K	0	0	384K	0	0	0	0	0
Interest Expense	13K	16K	648K	600K	384K	139K	113K	156K	302K	269K
Other Income/Expense	1.97M	4.12M	2.49M	38K	4.51M	-2.97M	4.06M	476K	-86K	-870K
Pretax Income+	-19.59M	-23.47M	-29.12M	-26.99M	-12.13M	-15.82M	-9.76M	-15.08M	-15.2M	-11.33M
Pretax Margin %	-2.26%	-1.65%	-3.96%	-2.38%	-0.87%	-1.78%	-0.87%	-1.17%	-0.83%	-0.63%
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-19.59M	-23.47M	-29.12M	-26.99M	-12.13M	-15.82M	-9.76M	-15.08M	-15.2M	-11.33M
Net Margin %	-2.26%	-1.65%	-3.96%	-2.38%	-0.87%	-1.78%	-0.87%	-1.17%	-0.83%	-0.63%
Net Income Growth %	0.42%	-0.2%	-0.24%	0.07%	0.55%	-0.3%	0.38%	-0.54%	-0.01%	0.25%
Net Income (Continuing)	-19.59M	-23.47M	-29.12M	-26.99M	-12.13M	-15.82M	-9.76M	-15.08M	-15.2M	-11.33M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-15.52	-18.90	-12.27	-6.61	-2.44	-2.21	-0.88	-1.16	-1.10	-0.56
EPS Growth %	0.56%	-0.22%	0.35%	0.46%	0.63%	0.09%	0.6%	-0.32%	0.05%	0.49%
EPS (Basic)	-15.53	-19.42	-12.27	-6.61	-2.44	-2.21	-0.80	-1.16	-1.10	-0.56
Diluted Shares Outstanding	1.26M	1.24M	2.37M	4.08M	4.79M	7.16M	12.27M	12.96M	13.87M	20.16M
Basic Shares Outstanding	1.26M	1.21M	2.37M	4.08M	4.79M	7.16M	12.19M	12.96M	13.87M	20.16M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	25.2M	20.68M	34.94M	14.97M	18.81M	18.42M	47.8M	31.04M	20.21M	18.84M
Cash & Short-Term Investments	19.55M	16.85M	27.81M	7.66M	10.87M	12.86M	40.41M	20.52M	8.64M	6.49M
Cash Only	19.55M	16.85M	27.81M	7.66M	10.87M	12.86M	40.41M	20.52M	8.64M	6.49M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	2.07M	1.78M	2.76M	3.66M	5.21M	3.39M	4.66M	4.63M	5.64M	7.24M
Days Sales Outstanding	87.19	45.69	137.01	117.89	136.59	139.27	151.31	130.74	112.72	147.38
Inventory	1.06M	1.56M	3.02M	3.37M	2.49M	1.98M	2.24M	5.19M	5.05M	4.57M
Days Inventory Outstanding	51.52	50.38	208.96	175.2	127.01	189.39	181.97	282.66	200.35	198.29
Other Current Assets	2.09M	502K	1.34M	281K	238K	191K	0	700K	875K	541K
Total Non-Current Assets+	7M	3.74M	3.05M	2.69M	3.11M	2.18M	1.37M	9.87M	8.71M	7.81M
Property, Plant & Equipment	2.63M	2.44M	2.25M	2.37M	2.74M	1.86M	1.21M	3.99M	3M	2.37M
Fixed Asset Turnover	3.30x	5.84x	3.27x	4.79x	5.08x	4.78x	9.32x	3.24x	6.10x	7.58x
Goodwill	189K	189K	189K	189K	189K	0	0	431K	431K	431K
Intangible Assets	1.58M	1.03M	491K	0	0	0	0	5.22M	4.89M	4.58M
Long-Term Investments	0	0	0	0	36K	0	0	0	0	0
Other Non-Current Assets	2.6M	91K	122K	134K	142K	320K	164K	231K	392K	433K
Total Assets+	32.2M	24.43M	37.99M	17.66M	21.91M	20.6M	49.17M	40.9M	28.92M	26.65M
Asset Turnover	0.27x	0.58x	0.19x	0.64x	0.64x	0.43x	0.23x	0.32x	0.63x	0.67x
Asset Growth %	-0.04%	-0.24%	0.56%	-0.54%	0.24%	-0.06%	1.39%	-0.17%	-0.29%	-0.08%
Total Current Liabilities+	8.62M	6.31M	9.16M	10.13M	7.83M	4.97M	6.86M	9.2M	8.12M	7.54M
Accounts Payable	2.69M	1.88M	2.42M	3.16M	1.9M	1.5M	3.11M	3.15M	1.85M	1.55M
Days Payables Outstanding	131.42	60.83	167.16	164.02	97.11	143.72	252.18	171.71	73.28	67.33
Short-Term Debt	80K	54K	2.14M	2.33M	2.77M	548K	0	2.31M	1.25M	1.25M
Deferred Revenue (Current)	1000K	825K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	682K	2.31M	1.24M	1.06M	567K	235K	0	0	606K	0
Current Ratio	2.92x	3.28x	3.81x	1.48x	2.40x	3.70x	6.97x	3.37x	2.49x	2.50x
Quick Ratio	2.80x	3.03x	3.48x	1.14x	2.08x	3.31x	6.65x	2.81x	1.87x	1.89x
Cash Conversion Cycle	7.29	35.23	178.8	129.06	166.49	184.94	81.1	241.69	239.8	278.35
Total Non-Current Liabilities+	14.77M	11.58M	7.43M	4.79M	7.29M	11.19M	5.09M	6.26M	8.2M	6.41M
Long-Term Debt	0	6.79M	4.83M	2.65M	407K	3.08M	1.99M	3.77M	4.83M	3.85M
Capital Lease Obligations	0	0	0	0	711K	233K	0	1.09M	723K	452K
Deferred Tax Liabilities	-21K	3.55M	1.65M	585K	0	0	0	0	0	0
Other Non-Current Liabilities	10.16M	3.99M	1.79M	652K	4.38M	6.08M	1.62M	374K	471K	182K
Total Liabilities	23.39M	17.89M	16.6M	14.93M	15.12M	16.16M	11.95M	15.46M	16.31M	13.95M
Total Debt+	80K	6.84M	7M	4.98M	3.89M	3.86M	2.22M	7.5M	7.17M	5.98M
Net Debt	-19.47M	-10M	-20.81M	-2.67M	-6.98M	-9.01M	-38.18M	-13.02M	-1.47M	-510K
Debt / Equity	0.01x	1.05x	0.33x	1.83x	0.57x	0.87x	0.06x	0.29x	0.57x	0.47x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-1658.54x	-1724.13x	-48.78x	-45.05x	-43.33x	-92.50x	-122.37x	-99.72x	-50.04x	-38.88x
Total Equity+	8.81M	6.53M	21.39M	2.73M	6.8M	4.43M	37.22M	25.44M	12.61M	12.71M
Equity Growth %	-0.61%	-0.26%	2.28%	-0.87%	1.49%	-0.35%	7.39%	-0.32%	-0.5%	0.01%
Book Value per Share	6.98	5.26	9.01	0.67	1.42	0.62	3.03	1.96	0.91	0.63
Total Shareholders' Equity	8.81M	6.53M	21.39M	2.73M	6.8M	4.43M	37.22M	25.44M	12.61M	12.71M
Common Stock	105K	22K	60K	63K	87K	8K	13K	13K	15K	22K
Retained Earnings	-91.39M	-114.86M	-144.15M	-171.15M	-183.28M	-199.1M	-208.87M	-223.95M	-239.15M	-250.47M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-1K	79K	-340K	-92K	50K	-847K	-17K	563K	156K	957K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-18.27M	-25M	-31.23M	-22.16M	-15.77M	-8.76M	-11.16M	-14.69M	-12.05M	-9.85M
Operating CF Margin %	-2.11%	-1.76%	-4.25%	-1.96%	-1.13%	-0.99%	-0.99%	-1.14%	-0.66%	-0.55%
Operating CF Growth %	-0.22%	-0.37%	-0.25%	0.29%	0.29%	0.44%	-0.27%	-0.32%	0.18%	0.18%
Net Income	-19.59M	-23.47M	-29.12M	-26.99M	-12.13M	-15.82M	-9.76M	-15.08M	-15.2M	-11.33M
Depreciation & Amortization	933K	1.85M	1.73M	1.51M	690K	620K	561K	887K	1.7M	1.61M
Stock-Based Compensation	1.73M	3.12M	2.92M	3.08M	2.4M	2.58M	2.5M	2.73M	2.24M	1.63M
Deferred Taxes	-2.5M	-4.15M	-3.24M	-606K	-5.87M	2.43M	-4.12M	0	0	0
Other Non-Cash Items	484K	-202K	55K	308K	1.16M	319K	134K	-647K	-207K	771K
Working Capital Changes	678K	-2.15M	-3.58M	530K	-2.02M	1.12M	-468K	-2.58M	-583K	-2.52M
Change in Receivables	-520K	154K	-1.08M	-850K	-1.6M	1.75M	-1.62M	-67K	-1.21M	-1.97M
Change in Inventory	-200K	-541K	-2.1M	-1.66M	893K	379K	-752K	-1.4M	232K	257K
Change in Payables	1.74M	-818K	77K	752K	-1.23M	-402K	1.61M	-102K	-1.31M	-288K
Cash from Investing+	-1.49M	-1.1M	-456K	-131K	-60K	0	-59K	-5.17M	-157K	-37K
Capital Expenditures	-1.49M	-1.1M	-456K	-131K	-60K	0	-59K	-194K	-157K	-37K
CapEx % of Revenue	0.17%	0.08%	0.06%	0.01%	0%	-	0.01%	0.02%	0.01%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	19K	0	0
Cash from Financing+	14.12M	23.31M	42.57M	2.27M	19.04M	10.7M	38.71M	0	348K	7.77M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	-10.35M	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	12.28M	159K	1K	228K	3.33M	1.42M	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-19.76M	-26.09M	-31.68M	-22.3M	-15.83M	-8.76M	-11.21M	-14.88M	-12.21M	-9.88M
FCF Margin %	-2.28%	-1.83%	-4.31%	-1.97%	-1.14%	-0.99%	-1%	-1.15%	-0.67%	-0.55%
FCF Growth %	-0.2%	-0.32%	-0.21%	0.3%	0.29%	0.45%	-0.28%	-0.33%	0.18%	0.19%
FCF per Share	-15.66	-21.02	-13.35	-5.46	-3.30	-1.22	-0.91	-1.15	-0.88	-0.49
FCF Conversion (FCF/Net Income)	0.93x	1.07x	1.07x	0.82x	1.30x	0.55x	1.14x	0.97x	0.79x	0.87x
Interest Paid	12K	16K	429K	457K	309K	109K	104K	126K	191K	182K
Taxes Paid	5K	33K	20K	18K	23K	6K	1K	13K	45K	8K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-123.96%	-306.02%	-208.6%	-223.82%	-254.74%	-281.81%	-46.88%	-48.13%	-79.89%	-89.52%
Return on Invested Capital (ROIC)	-	-	-	-6385.04%	-	-	-	-203.67%	-96.22%	-67.24%
Gross Margin	13.61%	20.72%	28.14%	38.03%	48.6%	57.08%	60.01%	48.13%	49.67%	53.06%
Net Margin	-226.19%	-165.04%	-396.06%	-238.19%	-87.17%	-178.17%	-86.82%	-116.79%	-83.14%	-63.21%
Debt / Equity	0.01x	1.05x	0.33x	1.83x	0.57x	0.87x	0.06x	0.29x	0.57x	0.47x
Interest Coverage	-1658.54x	-1724.13x	-48.78x	-45.05x	-43.33x	-92.50x	-122.37x	-99.72x	-50.04x	-38.88x
FCF Conversion	0.93x	1.07x	1.07x	0.82x	1.30x	0.55x	1.14x	0.97x	0.79x	0.87x
Revenue Growth	62.59%	64.2%	-48.29%	54.11%	22.81%	-36.18%	26.62%	14.81%	41.57%	-1.94%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Product	-	-	-	8.76M	10.79M	-	-	-	14.13M	-
Product Growth	-	-	-	-	23.13%	-	-	-	-	-
Service	-	-	-	2.1M	2.56M	-	-	-	2.82M	-
Service Growth	-	-	-	-	21.90%	-	-	-	-	-
Subscription	-	-	-	-	-	-	-	-	967K	-
Subscription Growth	-	-	-	-	-	-	-	-	-	-
Product and Service, Other	-	-	-	441K	493K	-	-	-	359K	-
Product and Service, Other Growth	-	-	-	-	11.79%	-	-	-	-	-
EksoHealth	-	-	-	-	-	8.07M	9.75M	11.83M	-	-
EksoHealth Growth	-	-	-	-	-	-	20.88%	21.33%	-	-
EksoWorks	-	-	-	-	-	816K	1.5M	1.08M	-	-
EksoWorks Growth	-	-	-	-	-	-	83.33%	-27.67%	-	-
Collaborative Arrangements	-	-	-	28K	74K	-	-	-	-	-
Collaborative Arrangements Growth	-	-	-	-	164.29%	-	-	-	-	-
Medical	-	-	5.83M	-	-	-	-	-	-	-
Medical Growth	-	-	-	-	-	-	-	-	-	-
Industrial	-	-	1.48M	-	-	-	-	-	-	-
Industrial Growth	-	-	-	-	-	-	-	-	-	-
Engineering Services	4.41M	887K	38K	-	-	-	-	-	-	-
Engineering Services Growth	-	-79.88%	-95.72%	-	-	-	-	-	-	-
Medical Devices	4.25M	12.08M	-	-	-	-	-	-	-	-
Medical Devices Growth	-	184.13%	-	-	-	-	-	-	-	-
Industrial Sales	-	1.25M	-	-	-	-	-	-	-	-
Industrial Sales Growth	-	-	-	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Americas	-	-	-	-	-	-	-	6.81M	-	10.13M
Americas Growth	-	-	-	-	-	-	-	-	-	-
UNITED STATES	-	-	-	7.03M	9.07M	5.95M	-	6.56M	-	9.71M
UNITED STATES Growth	-	-	-	-	29.07%	-34.46%	-	-	-	-
EMEA	-	-	-	-	-	-	-	3.85M	-	5.94M
EMEA Growth	-	-	-	-	-	-	-	-	-	-
FRANCE	-	-	-	-	-	-	-	-	-	3.01M
FRANCE Growth	-	-	-	-	-	-	-	-	-	-
Other Country	-	-	-	-	-	-	-	-	-	2.94M
Other Country Growth	-	-	-	-	-	-	-	-	-	-
Asia Pacific	-	-	-	-	-	-	-	2.25M	-	1.85M
Asia Pacific Growth	-	-	-	-	-	-	-	-	-	-
Americas Other	-	-	-	-	-	-	-	-	-	421K
Americas Other Growth	-	-	-	-	-	-	-	-	-	-
INDONESIA	-	-	-	-	-	-	-	-	18.28M	-
INDONESIA Growth	-	-	-	-	-	-	-	-	-	-
POLAND	-	-	-	-	-	-	-	-	1.41M	-
POLAND Growth	-	-	-	-	-	-	-	-	-	-
EMEA, Other	-	-	-	-	-	-	-	2.85M	-	-
EMEA, Other Growth	-	-	-	-	-	-	-	-	-	-
GERMANY	-	-	-	-	-	-	-	1M	-	-
GERMANY Growth	-	-	-	-	-	-	-	-	-	-
Americas, Other	-	-	-	-	-	-	-	252K	-	-
Americas, Other Growth	-	-	-	-	-	-	-	-	-	-
Non-US	-	-	-	4.3M	4.85M	2.94M	-	-	-	-
Non-US Growth	-	-	-	-	12.59%	-39.39%	-	-	-	-
United States	-	9.04M	4.96M	-	-	-	-	-	-	-
United States Growth	-	-	-45.17%	-	-	-	-	-	-	-
All Other	-	5.18M	2.4M	-	-	-	-	-	-	-
All Other Growth	-	-	-53.76%	-	-	-	-	-	-	-
North America	6.69M	-	-	-	-	-	-	-	-	-
North America Growth	-	-	-	-	-	-	-	-	-	-
Other Geographical	1.97M	-	-	-	-	-	-	-	-	-
Other Geographical Growth	-	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Ekso Bionics Holdings, Inc. (EKSO) reported $14.7M in revenue for fiscal year 2024. This represents a 347% increase from $3.3M in 2013.

Ekso Bionics Holdings, Inc. (EKSO) saw revenue decline by 1.9% over the past year.

Ekso Bionics Holdings, Inc. (EKSO) reported a net loss of $10.4M for fiscal year 2024.

Dividend & Returns

Ekso Bionics Holdings, Inc. (EKSO) has a return on equity (ROE) of -89.5%. Negative ROE indicates the company is unprofitable.

Ekso Bionics Holdings, Inc. (EKSO) had negative free cash flow of $8.9M in fiscal year 2024, likely due to heavy capital investments.